8月7日，Twist Bioscience盘中上涨5.43%，报114.465美元/股，成交额1851.88万美元。
消息面上，公司此前公布财年第三季度业绩，营收录得1.184亿美元，同比增长23.2%，超出分析师预期的1.145亿美元。更为关键的是，公司上调全年营收指引至4.56亿至4.57亿美元，并预计第四季度营收1.23亿至1.24亿美元，大幅高于FactSet一致预期的1.174亿美元。尽管每股亏损0.56美元不及市场预期的0.50美元，但远超预期的前瞻指引持续提振投资者信心。财报发布以来，股价经历剧烈多空博弈，此前Evercore ISI已于7月将公司评级下调至"与大市持平"，目标价上调至102美元，当前股价已突破该目标水平，今日反弹或反映市场重新聚焦收入增长势头。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.